Navigation Links
Two AIDS Vaccine Trials Hold Hope Against Epidemic

Twenty-five years into the AIDS epidemic, there's still no vaccine. Some hope is on the horizon but it could take at least 10 more years for any vaccine to enter the market. //

At a conference in Toronto that began Sunday, the world's HIV/AIDS groups plan to take stock of the discouraging race between the global medical community and the HIV virus that has killed millions worldwide.

Drug therapy has become a little more accessible, cheaper and easier to take for about 1.1 million people. However, it is still out of reach for most of the world's 40 million people infected with HIV/AIDS.

Stepping into the lurch with increasing promise is the field of topical microbicide gels that could kill the HIV virus in the vagina and protect women from infection.

The wealthy Rockefeller and Bill and Melinda Gates foundations poured start up money into the Maryland-based International Partnership for Microbicides (IPM) several years ago to pursue the idea.

"Now attention is focused on the fact that the epicentre of the epidemic is moving toward poor, married women," IPM spokeswoman Pam Norick said.

Vaccine development has been slow for good reason, according to Larry Corey, principal investigator of HIV Vaccine Trials Network (HVTN) based in Washington.

"The virus is a formidable foe with respect to its ability to change its outer coat, and we still have not learned how to make vaccines that make antibodies," Corey said in Seattle.

The most promising vaccine in three years targets the body's T-cells, and is being developed by Merck pharmaceuticals, according to Wayne Koff, an official at the International AIDS Vaccine Initiative (IAVI), which coordinates a network of global vaccine research projects.

Merck's vaccine, now in the last phase of testing on 3,000 volunteers in South America and the Caribbean, is an improvement over the disappointing Vaxgen that came to a dead en d in Thailand in 2003, Koff said.

Tests on the Merck vaccine, delivered to human volunteers using snippets of HIV DNA embedded in a modified common cold virus, could produce final data by 2007, putting it at the top of the pipeline, he said.

A second top candidate comes from the US National Institutes of Health (NIH), HVTN 204, and contains not only a wider variety of DNA from different parts of the virus but also snippets from the three leading global strains of HIV - the first promising candidate to offer such global potential.

It is being tested on 500 volunteers in North and South America, Africa and the Caribbean, vaccine project director Gary Nabel said.

"Realistically, if we have a licensed vaccine in less than 10 years, it would be pretty miraculous," Nabel told DPA.

In addition, a modified version of the Vaxgen trials continues on 16,000 volunteers in Thailand, who are receiving an added T-cell vaccine booster.

A lot depends on money. Global research gets about $800 million a year, an increase over funding levels three years ago but still short of the $1.1 billion needed, IAVI says.

To attract private firms like Merck to the unprofitable field, the US and other governments have provided funds - with the requirement that all results are shared.

For the vast majority of people with HIV, however, Acquired Immune Deficiency Syndrome (AIDS) is still a death sentence.

Only about 10 percent of those infected are aware of it, the Bill Clinton Foundation says, and treatment has fallen far short of the World Health Organization's goal of reaching three million HIV-positive people with life-prolonging medications by 2005.

(Source: IANS)
'"/>




Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce ... South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge ... of their homes, offices or at the practices’ local office. It is also one ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for American ... and wellness best practices in the past couple of decades, and food manufacturers ... Heart Month, which acts as an exceptional opportunity to revise food labels and ...
(Date:2/10/2016)... ... 10, 2016 , ... President Obama’s budget proposal yesterday enables ... medical services via telehealth, estimated to generate more than $160 million in savings ... many years. Although there is more to be done, this represents an ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... PLAD, Inc. (OTC Pink: PLAD) is pleased to announce ... company targets, are adding key personnel to their national ... United States Patent and Trademark Office for the characters ... of PLAD, Inc.  In January, PLAD established their presence ... with two new customers, Cumberland Goodwill EMS and Meadville ...
(Date:2/11/2016)... 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , ... an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the ...
Breaking Medicine Technology: